191 related articles for article (PubMed ID: 36564129)
1. Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies.
Kowalczyk JT; Fabian KP; Padget MR; Lopez DC; Hoke AT; Allen CT; Hermsen M; London NR; Hodge JW
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564129
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Gelbard A; Garnett CT; Abrams SI; Patel V; Gutkind JS; Palena C; Tsang KY; Schlom J; Hodge JW
Clin Cancer Res; 2006 Mar; 12(6):1897-905. PubMed ID: 16551875
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.
Bae SH; Park YJ; Park JB; Choi YS; Kim MS; Sin JI
Clin Cancer Res; 2007 Jan; 13(1):341-9. PubMed ID: 17200373
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway.
Sin JI; Kim JM; Bae SH; Lee IH; Park JS; Ryoo HM
Mol Ther; 2009 May; 17(5):906-13. PubMed ID: 19277009
[TBL] [Abstract][Full Text] [Related]
5. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
[TBL] [Abstract][Full Text] [Related]
6. Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.
Gameiro SR; Caballero JA; Hodge JW
Cancer Biother Radiopharm; 2012 Feb; 27(1):23-35. PubMed ID: 22316209
[TBL] [Abstract][Full Text] [Related]
7. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts.
Tseng CW; Trimble C; Zeng Q; Monie A; Alvarez RD; Huh WK; Hoory T; Wang MC; Hung CF; Wu TC
Cancer Immunol Immunother; 2009 May; 58(5):737-48. PubMed ID: 18815785
[TBL] [Abstract][Full Text] [Related]
8. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
Spanos WC; Nowicki P; Lee DW; Hoover A; Hostager B; Gupta A; Anderson ME; Lee JH
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1137-46. PubMed ID: 19917928
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
Lee SY; Kang TH; Knoff J; Huang Z; Soong RS; Alvarez RD; Hung CF; Wu TC
Cancer Immunol Immunother; 2013 Jul; 62(7):1175-85. PubMed ID: 23615841
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer.
Merritt RE; Mahtabifard A; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2003 Nov; 126(5):1609-17. PubMed ID: 14666041
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death.
van der Sluis TC; van Duikeren S; Huppelschoten S; Jordanova ES; Beyranvand Nejad E; Sloots A; Boon L; Smit VT; Welters MJ; Ossendorp F; van de Water B; Arens R; van der Burg SH; Melief CJ
Clin Cancer Res; 2015 Feb; 21(4):781-94. PubMed ID: 25501579
[TBL] [Abstract][Full Text] [Related]
12. Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer.
Vermeer DW; Spanos WC; Vermeer PD; Bruns AM; Lee KM; Lee JH
Int J Cancer; 2013 Jul; 133(1):120-9. PubMed ID: 23292955
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
Ramos CA; Narala N; Vyas GM; Leen AM; Gerdemann U; Sturgis EM; Anderson ML; Savoldo B; Heslop HE; Brenner MK; Rooney CM
J Immunother; 2013 Jan; 36(1):66-76. PubMed ID: 23211628
[TBL] [Abstract][Full Text] [Related]
14. Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16
Salomon N; Selmi A; Grunwitz C; Kong A; Stanganello E; Neumaier J; Petschenka J; Diken M; Kreiter S; Türeci Ö; Sahin U; Vascotto F
Cancer Immunol Immunother; 2022 Aug; 71(8):1975-1988. PubMed ID: 34971406
[TBL] [Abstract][Full Text] [Related]
15. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
[TBL] [Abstract][Full Text] [Related]
16. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.
Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK
Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
18. The Antitumor Efficiency of Zinc Finger Nuclease Combined with Cisplatin and Trichostatin A in Cervical Cancer Cells.
Ren C; Gao C; Li X; Xiong J; Shen H; Wang L; Zhu D; Wu P; Ding W; Wang H
Anticancer Agents Med Chem; 2020; 20(17):2125-2135. PubMed ID: 32753022
[TBL] [Abstract][Full Text] [Related]
19. A novel human in vitro papillomavirus type 16 positive tonsil cancer cell line with high sensitivity to radiation and cisplatin.
Forslund O; Sugiyama N; Wu C; Ravi N; Jin Y; Swoboda S; Andersson F; Bzhalava D; Hultin E; Paulsson K; Dillner J; Schwartz S; Wennerberg J; Ekblad L
BMC Cancer; 2019 Mar; 19(1):265. PubMed ID: 30909875
[TBL] [Abstract][Full Text] [Related]
20. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line.
Youde SJ; McCarthy CM; Thomas KJ; Smith KL; Man S
Int J Cancer; 2005 Apr; 114(4):606-12. PubMed ID: 15609329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
